Explore More at wakehealth.edu

Clinical and Translational Science Institute

Last Name

Thaddeus J. Wadas, Ph.D.

TitleAssistant Professor
InstitutionWake Forest School of Medicine
DepartmentCancer Biology
AddressHanes Building
Medical Center Blvd
vCardDownload vCard
    Other Positions
    TitleAssistant Professor
    InstitutionWake Forest School of Medicine
    DepartmentRadiologic Sciences-Medical Engineering

    Collapse Biography 
    Collapse education and training
    King'S College, Wilkes-Barre, PABS05/1998Biology/Chemistry
    University of Rochester, Rochester, NYMS05/2000Chemistry
    University of Rochester, Rochester, NYPhD05/2004Chemistry

    Collapse Overview 
    Collapse overview
    Cancer remains a leading cause of death in America, and presents an important public health challenge to the United States in terms of incidence, mortality and economic burden. My research program focuses on the development of radiopharmaceutical agents for cancer detection and therapy.

    Collapse Research 
    Collapse research activities and funding
    F32CA115148     (WADAS, THADDEUS J)Jul 1, 2005 - Dec 31, 2008
    Bone Metastasis Imaging with Copper-64-labeled Peptides
    Role: Principal Investigator

    W81XWH-13-1-0125     (Thaddeus Wadas)Jul 1, 2013 - Sep 1, 2017
    Department of Defense
    Prostate Cancer Imaging Using Positron Emission Tomography
    Role Description: The specific aims of this proposal are to develop PET imaging agents that detect prostate cancer by targeting biomarkers in the tumor microenvironment.
    Role: PI

         Jun 1, 2016 - May 31, 2019
    Melanoma Research Alliance Team Science Award in Uveal Melanoma
    Targeted Radiopharmaceutical for Uveal and Metastatic Melanoma
    Role Description: The goal of this study is to prepare 225Ac-labeled radiopharmaceuticals and evaluate their toxicity to normal tissues and their therapeutic efficacy in uveal melanoma
    Role: Co-Investigator

         (Thaddeus Wadas)Oct 1, 2016 - Jan 31, 2018
    North Carolina Biotechnology Center
    Stable Zirconium-89 Labeling of Monoclonal Antibodies —Enabling Positron Emission Tomography (PET) Scanning for Precision Medicine
    Role Description: The goal of this proposal is to demonstrate that our new process and ligands can be used to prepare clinically relevant 89Zr-immuno-PET agents that efficiently detect antigen positive tumors in vivo and have superior stability when compared to conventionally prepared 89Zr-immuno-PET agents.
    Role: PI

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Sattiraju A, Solingapuram Sai KK, Xuan A, Pandya DN, Almaguel FG, Wadas TJ, Herpai DM, Debinski W, Mintz A. IL13RA2 targeted alpha particle therapy against glioblastomas. Oncotarget. 2017 Jun 27; 8(26):42997-43007. PMID: 28562337.
      View in: PubMed
    2. Sattiraju A, Xiong X, Pandya DN, Wadas TJ, Xuan A, Sun Y, Jung Y, Sai KKS, Dorsey JF, Li KC, Mintz A. Alpha Particle Enhanced Blood Brain/Tumor Barrier Permeabilization in Glioblastomas Using Integrin Alpha-v Beta-3-Targeted Liposomes. Mol Cancer Ther. 2017 Oct; 16(10):2191-2200. PMID: 28619756.
      View in: PubMed
    3. Bhatt NB, Pandya DN, Xu J, Tatum D, Magda D, Wadas TJ. Evaluation of macrocyclic hydroxyisophthalamide ligands as chelators for zirconium-89. PLoS One. 2017; 12(6):e0178767. PMID: 28575044.
      View in: PubMed
    4. Sun Y, Xiong X, Pandya D, Jung Y, Mintz A, Hayasaka S, Wadas TJ, Li KCP. Enhancing tissue permeability with MRI guided preclinical focused ultrasound system in rabbit muscle: From normal tissue to VX2 tumor. J Control Release. 2017 Jun 28; 256:1-8. PMID: 28412225.
      View in: PubMed
    5. Pandya DN, Bhatt N, Yuan H, Day CS, Ehrmann BM, Wright M, Bierbach U, Wadas TJ. Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development. Chem Sci. 2017 Mar 01; 8(3):2309-2314. PMID: 28451334.
      View in: PubMed
    6. Pandya DN, Hantgan R, Budzevich MM, Kock ND, Morse DL, Batista I, Mintz A, Li KC, Wadas TJ. Preliminary Therapy Evaluation of (225)Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from (225)Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization. Theranostics. 2016; 6(5):698-709. PMID: 27022417; PMCID: PMC4805664.
    7. N Tinianow J, Pandya DN, Pailloux SL, Ogasawara A, Vanderbilt AN, Gill HS, Williams SP, Wadas TJ, Magda D, Marik J. Evaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) Based Macrocyclic Chelator for (89)Zr(4+) and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice. Theranostics. 2016; 6(4):511-21. PMID: 26941844; PMCID: PMC4775861.
    8. Sattiraju, A (Sattiraju, Anirudh); Xiong, XB (Xiong, Xiaobing); Pandya, D (Pandya, Darpan); Sun, Y (Sun, Yao); Jung, Y (Jung, Youngkyoo); Wadas, T (Wadas, Thaddeus); Li, K (Li, King); Mintz, A (Mintz, Akiva). Journal of Nuclear Medicine. Permeabilizing the blood-brain-barrier with alpha-particle therapy. 2015; 56(3):1230.
    9. Lears KA, Parry JJ, Andrews R, Nguyen K, Wadas TJ, Rogers BE. Adenoviral-mediated imaging of gene transfer using a somatostatin receptor-cytosine deaminase fusion protein. Cancer Gene Ther. 2015 Mar; 22(4):215-21. PMID: 25837665; PMCID: PMC4409539.
    10. Pandya DN, Pailloux S, Tatum D, Magda D, Wadas TJ. Di-macrocyclic terephthalamide ligands as chelators for the PET radionuclide zirconium-89. Chem Commun (Camb). 2015 Feb 11; 51(12):2301-3. PMID: 25556851; PMCID: PMC4507282.
    11. Wadas TJ, Pandya DN, Solingapuram Sai KK, Mintz A. Molecular targeted a-particle therapy for oncologic applications. AJR Am J Roentgenol. 2014 Aug; 203(2):253-60. PMID: 25055256; PMCID: PMC4490786.
    12. Pandya D, Magda D, Raymond K, Wadas, T. Journal of Nuclear Medicine. Radiochemistry and biological evaluation of novel 2-hydroxyisophthalamide and 3-hydroxy-2-oxopyridine ligands as chelators for Zr-89. 2014; 55(Suppl 1):1186.
    13. Pandya D, Batista I, Zhu DQ, Mintz A, Wadas T. Radiochemistry and biological evaluation of Ac-225-DOTA-c(RGDyK), a potential radiopharmaceutical for targeted alpha particle therapy. Journal of Nuclear Medicine. 2014; 55(Suppl 1):1477.
    14. Zheleznyak A, Wadas TJ, Sherman CD, Wilson JM, Kostenuik PJ, Weilbaecher KN, Anderson CJ. Integrin a(v)ß3 as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation. Mol Imaging Biol. 2012 Aug; 14(4):500-8. PMID: 21853370; PMCID: PMC4277818.
    15. Shokeen M, Wadas TJ. The development of copper radiopharmaceuticals for imaging and therapy. Med Chem. 2011 Sep; 7(5):413-29. PMID: 21711219.
      View in: PubMed
    16. Odendaal AY, Fiamengo AL, Ferdani R, Wadas TJ, Hill DC, Peng Y, Heroux KJ, Golen JA, Rheingold AL, Anderson CJ, Weisman GR, Wong EH. Isomeric trimethylene and ethylene pendant-armed cross-bridged tetraazamacrocycles and in vitro/in vivo comparisions of their copper(II) complexes. Inorg Chem. 2011 Apr 04; 50(7):3078-86. PMID: 21381676; PMCID: PMC3065210.
    17. Wadas TJ, Sherman CD, Miner JH, Duncan JR, Anderson CJ. The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice. Magn Reson Med. 2010 Nov; 64(5):1274-80. PMID: 20648683; PMCID: PMC3180881.
    18. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010 May 12; 110(5):2858-902. PMID: 20415480; PMCID: PMC2874951.
    19. Wadas TJ, Deng H, Sprague JE, Zheleznyak A, Weilbaecher KN, Anderson CJ. Targeting the alphavbeta3 integrin for small-animal PET/CT of osteolytic bone metastases. J Nucl Med. 2009 Nov; 50(11):1873-80. PMID: 19875645; PMCID: PMC2836828.
    20. Barnard PJ, Holland JP, Bayly SR, Wadas TJ, Anderson CJ, Dilworth JR. Macrocyclic diamide ligand systems: potential chelators for 64Cu- and 68Ga-based positron emission tomography imaging agents. Inorg Chem. 2009 Aug 03; 48(15):7117-26. PMID: 19588930; PMCID: PMC4287963.
    21. Wei L, Ye Y, Wadas TJ, Lewis JS, Welch MJ, Achilefu S, Anderson CJ. (64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity. Nucl Med Biol. 2009 Apr; 36(3):277-85. PMID: 19324273; PMCID: PMC2692938.
    22. Wadas TJ, Eiblmaier M, Zheleznyak A, Sherman CD, Ferdani R, Liang K, Achilefu S, Anderson CJ. Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors. J Nucl Med. 2008 Nov; 49(11):1819-27. PMID: 18927338; PMCID: PMC2794832.
    23. Anderson CJ, Wadas TJ, Wong EH, Weisman GR. Cross-bridged macrocyclic chelators for stable complexation of copper radionuclides for PET imaging. Q J Nucl Med Mol Imaging. 2008 Jun; 52(2):185-92. PMID: 18043536; PMCID: PMC4286870.
    24. Heroux KJ, Woodin KS, Tranchemontagne DJ, Widger PC, Southwick E, Wong EH, Weisman GR, Tomellini SA, Wadas TJ, Anderson CJ, Kassel S, Golen JA, Rheingold AL. The long and short of it: the influence of N-carboxyethyl versusN-carboxymethyl pendant arms on in vitro and in vivo behavior of copper complexes of cross-bridged tetraamine macrocycles. Dalton Trans. 2007 Jun 07; (21):2150-62. PMID: 17514336; PMCID: PMC4289607.
    25. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des. 2007; 13(1):3-16. PMID: 17266585.
      View in: PubMed
    26. Wadas TJ, Anderson CJ. Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64. Nat Protoc. 2006; 1(6):3062-8. PMID: 17406569.
      View in: PubMed
    27. Chakraborty S, Wadas TJ, Hester H, Schmehl R, Eisenberg R. Platinum chromophore-based systems for photoinduced charge separation: a molecular design approach for artificial photosynthesis. Inorg Chem. 2005 Oct 03; 44(20):6865-78. PMID: 16180842.
      View in: PubMed
    28. Chakraborty S, Wadas TJ, Hester H, Flaschenreim C, Schmehl R, Eisenberg R. Synthesis, structure, characterization, and photophysical studies of a new platinum terpyridyl-based triad with covalently linked donor and acceptor groups. Inorg Chem. 2005 Sep 05; 44(18):6284-93. PMID: 16124807.
      View in: PubMed
    29. Wadas TJ, Chakraborty S, Lachicotte RJ, Wang QM, Eisenberg R. Facile synthesis, structure, and luminescence properties of Pt(diimine)bis(arylacetylide) chromophore-donor dyads. Inorg Chem. 2005 Apr 18; 44(8):2628-38. PMID: 15819547.
      View in: PubMed
    30. Wadas TJ, Wang QM, Kim YJ, Flaschenreim C, Blanton TN, Eisenberg R. Vapochromism and its structural basis in a luminescent Pt(II) terpyridine-nicotinamide complex. J Am Chem Soc. 2004 Dec 29; 126(51):16841-9. PMID: 15612723.
      View in: PubMed
    31. Wadas TJ, Lachicotte RJ, Eisenberg R. Synthesis and characterization of platinum diimine bis(acetylide) complexes containing easily derivatizable aryl acetylide ligands. Inorg Chem. 2003 Jun 16; 42(12):3772-8. PMID: 12793813.
      View in: PubMed
    Wadas's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description
    Physical Neighbors Expand Description